Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
447.50    -11.50 (-2.51%)
Bid:
449.00
Ask:
451.50
Spread: 2.50 (0.557%)
Market Cap: £220.09m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Director/PDMR Shareholding

22 Dec 2017 12:27

RNS Number : 2540A
Zotefoams PLC
22 December 2017
 

Zotefoams plc (the 'Company')

 

Directors' Shareholdings

 

On 20 December 2017, David Stirling, Group CEO, exercised his option under the Company's Approved Share Option Plan over 28,116 Ordinary Shares of 5p ('Shares') each in the capital of the Company at an exercise price of £1.067 per share. Mr Stirling sold all the Shares on 20 December 2017 at a price of £4.55 per share.

 

The Company was notified on 20 December 2017 that Mr Douglas Robertson, a Non-Executive Director of the Company, bought 5,416 Ordinary shares of 5p each in the Company on 20 December 2017 at a price of £4.59 per share.

 

Following this purchase, Mr Robertson is interested in 5,416 Ordinary Shares, representing just over 0.01% of the Company's issued share capital. Mr Stirling's shareholding remains unchanged.

 

The Notification of Dealing Forms can be found below.

 

This notification is made in accordance with the Market Abuse Regulation.

 

Enquiries:

James Kindell

Company Secretary

Zotefoams plc

 

22 December 2017

 

020 8664 1600

 

About Zotefoams plc:

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

 

ZOTEFOAMS PLC

DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: David Stirling

2.

Reason for the notification

a)

Position/status: Group CEO

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise of an option under the Approved Share Option Plan

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£1.067

28,116

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£1.067

28,116

£29,999.77

e)

Date of the transaction: 2017-12-20

f)

Place of the transaction: Outside a trading venue

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Sale of shares from exercising an option under the Approved Share Option Plan.

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£4.55

28,116

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£4.55

28,116

£127,927.80

e)

Date of the transaction: 2017-12-20, 15:19:00

f)

Place of the transaction: XLON / BATE / CHIX / TRQX

 

ZOTEFOAMS PLC

DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Douglas Robertson

2.

Reason for the notification

a)

Position/status: Non-Executive Director

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Purchase of shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£4.59

5,416

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£4.59

5,416

£24,859.44

e)

Date of the transaction: 2017-12-20; 12.33.07

f)

Place of the transaction: XLON / BATE / CHIX / TRQX

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAAAAAAKXFFF
Date   Source Headline
12th May 20117:00 amRNSAGM Statement
3rd May 201112:54 pmRNSTotal Voting Rights
13th Apr 20115:01 pmRNSNotice of AGM
4th Apr 201111:04 amRNSDirector/PDMR Shareholding
31st Mar 20113:04 pmRNSDirector/PDMR Shareholding
31st Mar 20117:00 amRNSAcquisition of MuCell and Share Placing
23rd Mar 20113:24 pmRNSDirector/PDMR Shareholding
8th Mar 20117:00 amRNSFinal Results
14th Feb 20113:47 pmRNSHolding(s) in Company
4th Jan 20113:00 pmRNSHolding(s) in Company
22nd Dec 20103:49 pmRNSHolding(s) in Company
21st Dec 20107:00 amRNSTrading Statement
16th Dec 201012:11 pmRNSHolding(s) in Company
2nd Dec 20109:32 amRNSDirectorate Change
17th Nov 20103:55 pmRNSHolding(s) in Company
17th Nov 20103:52 pmRNSHolding(s) in Company
12th Nov 20103:05 pmRNSDirector/PDMR Shareholding
22nd Oct 20107:00 amRNSInterim Management Statement
22nd Oct 20107:00 amRNSInterim Management Statement
12th Oct 20108:14 amRNSHolding(s) in Company
28th Sep 20105:41 pmRNSHolding(s) in Company
28th Sep 20105:39 pmRNSHolding(s) in Company
28th Sep 20101:00 pmRNSHolding(s) in Company
27th Sep 20103:02 pmRNSHolding(s) in Company
11th Aug 201010:57 amRNSHolding(s) in Company
9th Aug 20103:27 pmRNSHolding(s) in Company
3rd Aug 20107:00 amRNSHalf Yearly Report
1st Jul 20107:00 amRNSTrading Statement
9th Jun 201012:24 pmRNSHolding in company - amendment
9th Jun 201010:32 amRNSHolding(s) in Company
28th May 20103:31 pmRNSAnnual Information Update
17th May 20107:00 amRNSDirector/PDMR Shareholding
13th May 20103:00 pmRNSResult of AGM
11th May 20107:00 amRNSAGM Statement
7th May 20104:06 pmRNSDirector/PDMR Shareholding
12th Apr 20107:00 amRNSNotice of AGM
7th Apr 20104:30 pmRNSDirector/PDMR Shareholding
29th Mar 20108:50 amRNSHolding(s) in Company
24th Mar 201012:46 pmRNSHolding(s) in Company
23rd Mar 20102:40 pmRNSDirector/PDMR Shareholding
15th Mar 20104:52 pmRNSDirector/PDMR Shareholding
9th Mar 20107:00 amRNSFinal Results
3rd Mar 20102:36 pmRNSHolding(s) in Company
10th Dec 20092:30 pmRNSTrading Statement
23rd Oct 20097:00 amRNSInterim Management Statement
9th Oct 20093:08 pmRNSHolding(s) in Company
8th Sep 20092:13 pmRNSHolding(s) in Company
18th Aug 20091:36 pmRNSDirector/PDMR Shareholding
11th Aug 20095:45 pmRNSHolding(s) in Company
11th Aug 20095:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.